Skip Navigation



NDT Advance Access published online on September 28, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm467
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/12/3656    most recent
gfm467v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by D’Ythurbide, G.
Right arrow Articles by Snanoudj, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D’Ythurbide, G.
Right arrow Articles by Snanoudj, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review

Géraldine D’Ythurbide1, Cécile Goujard2, Frédéric Méchaï2, Arnaud Blanc2, Bernard Charpentier1,3 and Renaud Snanoudj1,3

1Department of Nephrology, 2Department of Internal Medicine, Kremlin-Bicêtre Hospital, AP-HP, Le Kremlin-Bicêtre and 3INSERM UMR 542, Paris-Sud University, Paul Brousse Hospital, Villejuif, France

Correspondence and offprint requests to: Dr Renaud Snanoudj, Service de Néphrologie, CHU Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. Email: renaud.snanoudj@bct.aphp.fr

Keywords: Fanconi syndrome; nephrogenic diabetes insipidus; drugs nephrotoxicity; HIV infection

The first 150 words of the full text of this article appear below.

HIV-infected patients are now treated with combined antiretroviral therapy (CART). Many drugs and/or metabolites are excreted by the kidneys. Furthermore, HIV-infected patients have a high prevalence of pre-existing nephropathies, which may or may not be related to HIV [1].

The nucleotide reverse transcriptase inhibitor tenofovir induces tubulopathies and renal insufficiency [2–4]. Nucleoside analogs essentially have mitochondrial toxicity. Nephrotoxicity of these nucleoside analogs is rare. Indeed, didanosine has a good kidney safety profile and only two cases of severe tubular toxicity have been reported [5,6]. Various authors have raised questions about the cumulative nephrotoxicity of didanosine and tenofovir and their respective roles, as their association leads to unexpected side effects in the kidney [7].

Here, we report a case of Fanconi syndrome and nephrogenic diabetes insipidus in an HIV-infected patient receiving a CART regimen including didanosine. We also review the cases . . . [Full Text of this Article]



   Case report
 


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NDT PlusHome page
N. Fontsere, C. Guerrero, V. Esteve, M. Sole, and M. R. de Arellano
Proximal tubular dysfunction associated with tenofovir in an HVC-HIV co-infected patient undergoing HVC therapy
NDT Plus, August 1, 2008; 1(4): 271 - 272.
[Full Text] [PDF]